Bryan Peacker
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2026
Year:
2026
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies. Significance: The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
Year:
2026
While immunotherapy has been widely adopted for the treatment of melanoma, its application in patients with complex comorbidities remains challenging. This review explores evidence on the efficacy, safety, and special considerations for the use of immunotherapy in patients with altered immune systems, including patients with human immunodeficiency virus (HIV), tuberculosis, solid organ or hematopoietic cell transplantation, autoimmune diseases, and pregnant women. Despite data emphasizing the feasibility of immunotherapy treatment in these populations, standardized management algorithms are lacking. Future research should consider either including these patients in prospective trials or attempting to collect data via registries to provide more clarity on the management of immunologically vulnerable patients with melanoma.
Year:
2026
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P Significance: The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
Year:
2026
Kaplan–Meier curves for survival outcomes in patients with MSS/pMMR mCRC receiving ICI-based therapies, stratified by liver metastasis status at the time of ICI initiation. A, PFS: Patients without liver metastases had significantly higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median PFS was 2.1 months (95% CI, 1.59–2.62) in those with liver metastases and 2.5 months (95% CI, 2.22–2.71) in those without liver metastases (HR, 1.68; 95% CI, 1.13–2.5; P = 0.009). B, OS: Median OS was 11.53 months (95% CI, 3.01–20.06) in those without liver metastases and 6.17 months (95% CI, 2.87–9.46) in those with liver metastases (HR, 2.03; 95% CI, 1.35–3.06; P
Year:
2026
Year:
2025
Background Skin diseases contribute significantly to morbidity worldwide, yet their burden in North Africa and the Middle East (NAME) remains poorly understood. This study aims to assess the burden of skin diseases in NAME from 1990 to 2021. Methods Using data from the Global Burden of Disease (GBD) study, we analyzed disability‐adjusted life‐years (DALYs) and age‐adjusted prevalence, incidence, and mortality rates of 23 skin conditions across 21 NAME countries from 1990 to 2021. Results In 2021, skin and subcutaneous diseases ranked as the 22nd leading cause of morbidity and mortality in NAME, with a 0.06% increase in DALYs since 1990 (95% confidence interval [CI]: 0.05%–0.08%). The most prevalent skin conditions (age‐adjusted per 100,000) were other skin and subcutaneous diseases (6788.41), fungal skin diseases (3311.44), acne vulgaris (3102.51), atopic dermatitis (1374.93), viral skin diseases (1257.88), scabies (1009.72), contact dermatitis (998.89), pruritus (980.93), urticaria (936.13), and cutaneous leishmaniasis (642.73). Qatar experienced the largest DALYs increase in skin disease (0.12%; 95% CI: 0.07%–0.18%). Notable geographic variations included increased DALYs for acne vulgaris, psoriasis, and viral skin diseases across all countries; a rise in cutaneous leishmaniasis in Afghanistan, Syria, and Morocco; and a decline in measles, varicella‐herpes zoster, and leprosy (except in Iran). Conclusion Skin diseases impose a significant and evolving burden in NAME, with notable temporal and geographic variations. Further research is needed to better understand disease epidemiology and guide future interventions.
Year:
2025
Year:
2025
Hematopoietic stem cells (HSCs) are self-renewing, multipotent, and engraftable precursors of all blood cells. Efficient delivery of therapeutic gene products and gene editing machinery to correct disease-causing gene variants in endogenous HSCs while they remain in the body holds exciting potential to leverage HSC potency for the treatment of monogenic blood disorders. Toward this goal, we used adeno-associated virus (AAV) to deliver CRISPR guide RNAs (gRNAs) to edit HSC genomes in situ in Ai9;SpCas9-EGFP transgenic mice carrying a Cas9-activatable Lox-STOP-Lox-tdTomato reporter cassette together with a constitutive SpCas9-2A-EGFP. Using a variety of conditions and vector designs, we tested whether systemic administration to these mice of AAVs carrying SpCas9-compatible gRNAs designed to cut DNA upstream and downstream of the STOP cassette would induce tdTomato expression in HSCs. Our findings identify self-complementary AAVs (scAAVs) and increased ratio of guide to Cas9 as parameters facilitating higher editing efficiency. Of note, we find preserved multilineage output and engraftability of HSCs upon scAAV-gRNA editing. In an example application of this technology, we explore the potential for in situ HSC gene editing by dual AAV-CRISPR delivery and demonstrate robust gene modification, concurrent with induction of therapeutic fetal hemoglobin, in a sickle cell disease mouse model modified to express SpCas9. In summary, this work offers a sensitive and adaptable platform that allows robust modification of HSC genomes in situ.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2022
Year:
2022
Year:
2021
Collaborators (7)
Kevin Sheng-Kai Ma
Harvard T.H. Chan School of Public Health
Natalie Baker
Stanford University
Amy Wagers
Professor
Harvard University
Jeffrey Clark
Associate Professor
Harvard University
Motaz Qadan
Hepatobiliary and Pancreatic Surgical Oncologist
Massachusetts General Hospital
Lee Wheless
Assistant Professor
Vanderbilt University Medical Center
David Ting
Associate Professor of Medicine
-
Make your next move.
Prepare your application
Review drafts before you send them.